Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Optical Coherence Tomography in Multiple Sclerosis Patients
Optical Coherence Tomography in Multiple Sclerosis Patients
Status: Enrolling
Updated:  1/19/2013
Cole Eye Institute
mi
from
Cleveland, OH
Optical Coherence Tomography in Multiple Sclerosis Patients
Optical Coherence Tomography in Multiple Sclerosis Patients
Status: Enrolling
Updated: 1/19/2013
Cole Eye Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 111
mi
from
Gilbert, AZ
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 111
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 139
mi
from
Downey, CA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 139
mi
from
Downey, CA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 112
mi
from
Irvine, CA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 112
mi
from
Irvine, CA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 119
mi
from
Long Beach, CA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 119
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 134
mi
from
Fairfield, CT
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 134
mi
from
Fairfield, CT
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 124
mi
from
New London, CT
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 124
mi
from
New London, CT
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 114
mi
from
Maitland, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 114
mi
from
Maitland, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 120
mi
from
Port Charlotte, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 120
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 130
mi
from
Sunrise, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 130
mi
from
Sunrise, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 115
mi
from
Tampa, FL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 115
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 107
mi
from
Elk Grove Village, IL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 107
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 132
mi
from
Northbrook, IL
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 132
mi
from
Northbrook, IL
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 118
mi
from
Kansas City, KA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 118
mi
from
Kansas City, KA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 140
mi
from
Louisville, KY
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 140
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 103
mi
from
Golden Valley, MN
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 103
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 125
mi
from
Charlotte, NC
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 125
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 141
mi
from
Raleigh, NC
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 141
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 106
mi
from
Cleveland, OH
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 106
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 135
mi
from
Dayton, OH
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 135
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 132
mi
from
Abington, PA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 132
mi
from
Abington, PA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 109
mi
from
Indiana, PA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 109
mi
from
Indiana, PA
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 137
mi
from
Franklin, TN
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 137
mi
from
Franklin, TN
Click here to add this to my saved trials
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated:  1/31/2013
Synthon investigational site 122
mi
from
Charlottesville, VA
Efficacy and Safety of GTR in Comparison to Copaxone®
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Status: Enrolling
Updated: 1/31/2013
Synthon investigational site 122
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis
Validation of a Hand-Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Status: Enrolling
Updated:  2/4/2013
MS Center at Evergreen Hospital
mi
from
Kirkland, WA
Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis
Validation of a Hand-Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
Status: Enrolling
Updated: 2/4/2013
MS Center at Evergreen Hospital
mi
from
Kirkland, WA
Click here to add this to my saved trials
Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist
Comparing Lesion Contrast With Both Magnevist and Gadavist and Understanding the Cerebral Perfusion Patterns of Patients With Multiple Sclerosis (MS) Using Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated:  4/16/2013
Wayne State University
mi
from
Detroit, MI
Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist
Comparing Lesion Contrast With Both Magnevist and Gadavist and Understanding the Cerebral Perfusion Patterns of Patients With Multiple Sclerosis (MS) Using Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated: 4/16/2013
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis
Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis
Status: Enrolling
Updated:  4/19/2013
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis
Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis
Status: Enrolling
Updated: 4/19/2013
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  6/5/2013
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 6/5/2013
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  6/17/2013
Michigan Institute for Neurological Disorders (M.I.N.D.)
mi
from
Farmington Hills, MI
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 6/17/2013
Michigan Institute for Neurological Disorders (M.I.N.D.)
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  6/17/2013
Buffalo Neuroimaging Analysis Center (BNAC)
mi
from
Buffalo, NY
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 6/17/2013
Buffalo Neuroimaging Analysis Center (BNAC)
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  6/17/2013
UT Southwestern Medical Center
mi
from
Dallas, TX
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 6/17/2013
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Testosterone Treatment for Multiple Sclerosis
Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial
Status: Enrolling
Updated:  7/11/2013
University of California at Los Angeles
mi
from
Los Angeles, CA
Testosterone Treatment for Multiple Sclerosis
Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial
Status: Enrolling
Updated: 7/11/2013
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Aspirin for Treatment of Multiple Sclerosis-Related Fatigue
Aspirin for Treatment of Multiple Sclerosis-Related Fatigue
Status: Enrolling
Updated:  7/15/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Aspirin for Treatment of Multiple Sclerosis-Related Fatigue
Aspirin for Treatment of Multiple Sclerosis-Related Fatigue
Status: Enrolling
Updated: 7/15/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Comprehensive Analysis of Relapse in Multiple Sclerosis
Comprehensive Analysis of Relapse in Multiple Sclerosis
Status: Enrolling
Updated:  7/31/2013
Tanner Center for MS
mi
from
Birmingham, AL
Comprehensive Analysis of Relapse in Multiple Sclerosis
Comprehensive Analysis of Relapse in Multiple Sclerosis
Status: Enrolling
Updated: 7/31/2013
Tanner Center for MS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Adherence Trial With MS LifeLines ® Services
A Prospective, Parallel Group, Phase IV Study of Three Levels of MS LifeLines ® Support Services Provided to Patients Prescribed Rebif ® for Newly Diagnosed or First-switch Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  8/4/2013
Call EMD Serono Medical Information for information on recruiting sites
mi
from
Boston, MA
Adherence Trial With MS LifeLines ® Services
A Prospective, Parallel Group, Phase IV Study of Three Levels of MS LifeLines ® Support Services Provided to Patients Prescribed Rebif ® for Newly Diagnosed or First-switch Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 8/4/2013
Call EMD Serono Medical Information for information on recruiting sites
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Cullman, AL
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Cullman, AL
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Sacramento, CA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Stanford, CA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Stanford, CA
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Fairfield, CT
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Fairfield, CT
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
North Haven, CT
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
North Haven, CT
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Lenexa, KA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Lenexa, KA
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Ann Arbor, MI
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Farmington Hills, MI
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis
mi
from
Portland, OR
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Cordova, TN
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Cordova, TN
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Nashville, TN
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Salt Lake City, UT
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials